David F. McDermott spends much of his time researching Internal medicine, Renal cell carcinoma, Surgery, Oncology and Nivolumab. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Melanoma. His Renal cell carcinoma research includes themes of Carcinoma and Antibody.
His Surgery research incorporates elements of Urology and Hazard ratio. His work carried out in the field of Oncology brings together such families of science as Tolerability, Atezolizumab and Response Evaluation Criteria in Solid Tumors. David F. McDermott combines subjects such as Clinical trial, Blockade, Everolimus, Lung cancer and Pharmacology with his study of Nivolumab.
His scientific interests lie mostly in Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and In patient. His Internal medicine study incorporates themes from Melanoma and Surgery. His study in Surgery is interdisciplinary in nature, drawing from both Gastroenterology, Hazard ratio, Toxicity and Urology.
His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Targeted therapy, Immunotherapy and Clinical trial, Phases of clinical research. The Renal cell carcinoma study combines topics in areas such as Bevacizumab, Cancer research and Carcinoma. The various areas that David F. McDermott examines in his Nivolumab study include Discontinuation, Antibody and Everolimus.
David F. McDermott mostly deals with Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and In patient. Internal medicine is a component of his Pembrolizumab, Adverse effect, Clear cell renal cell carcinoma, Clinical trial and Axitinib studies. His studies in Pembrolizumab integrate themes in fields like Colorectal cancer, Combination therapy and Cohort.
His study looks at the relationship between Oncology and fields such as Advanced melanoma, as well as how they intersect with chemical problems. David F. McDermott has included themes like Bevacizumab, Cancer research, Atezolizumab and Checkmate in his Renal cell carcinoma study. His Nivolumab study deals with Ipilimumab intersecting with First line treatment, Gastroenterology and Vemurafenib.
David F. McDermott mainly focuses on Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and Ipilimumab. His Oncology research includes themes of Survival rate, Adverse effect and Clinical trial, Phases of clinical research. The study incorporates disciplines such as Pharmacokinetics, Tolerability, Blockade and Atezolizumab in addition to Renal cell carcinoma.
His Blockade study combines topics from a wide range of disciplines, such as Cancer, Cancer research and Antibody. His work on Checkmate is typically connected to In patient as part of general Nivolumab study, connecting several disciplines of science. His work is dedicated to discovering how Ipilimumab, Targeted therapy are connected with Vemurafenib, Dabrafenib, Cobimetinib, Sarcomatoid Features and Post hoc and other disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber.
The New England Journal of Medicine (2010)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger.
The New England Journal of Medicine (2012)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher.
The New England Journal of Medicine (2007)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George.
The New England Journal of Medicine (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert.
The New England Journal of Medicine (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger.
Journal of Clinical Oncology (2014)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera.
The New England Journal of Medicine (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins.
Journal of Clinical Oncology (2018)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren.
Journal of Clinical Oncology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: